| Author (Corporate) | European Medicines Agency |
|---|---|
| Series Title | Press Release |
| Series Details | EMA/CHMP/648226/2010 (21.10.10) |
| Publication Date | 21/10/2010 |
| Content Type | News |
|
The European Medicines Agency announced on 21 October 2010 that its Committee for Medicinal Products for Human Use (CHMP) had reviewed all available data on Invirase (saquinavir) and the potential risk of arrhythmia, and concluded that 'the benefit of the medicine continues to outweigh its risks.' Ritonavir-boosted Invirase in combination with other antiretroviral medicines is indicated for the treatment of HIV-infected adult patients. |
|
| Source Link | Link to Main Source http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/10/WC500098345.pdf |
| Related Links |
|
| Subject Categories | Health |
| Countries / Regions | Europe |
